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COMPARATIVE   STUDY   BETWEEN  TRANSURETHRAL  RESECTION
(TURP) AND   TRANSURETHRAL  INCISION   (TUIP)   OF   THE
PROSTATE   FOR  SMALL SIZE BENIGN   PROSTATIC  HYPERPLASIA
ABSTRACT
AIM
To    evaluate    the   efficacy   of   TUIP   as   a   treatment   modality   for
small   size   obstructive   BPH   and   to   compare   its outcome with that of TURP
OBJECTIVES
To optimize treatment modality of small size obstructive BPH with minimally
invasive procedure
MATERIALS AND METHODS:
1. Study group   :
Patients who were admitted with bothersome lower urinary tract symptoms
(LUTS)  due to benign prostatic hyperplasia at 1. Kilpauk Medical College Hospital
and  2. Government RoyapettahHospital between 2010 - 2011were included in the
study group.
2. Study design :      Prospective Randomised  Clinical study
3. Materials :
60 patients were included in our study who fulfilled our selection criteria. They
were randomly selected into two groups (Group 1- TUIP, Group 2 – TURP). The two
groups were analysed for statistical equality. Mean of age – 67.54 years and 65.07
years, gland size – 28.58 and 29.44 grams, IPSS – 25.73 and 25.41, QOL – 4.23 and
4.15 Peak uroflowmetry – 6.23ml and 6.36ml, post void residual urine – 128 and 114
ml in TUIP and TURP respectively which were statistically not significant.
Preoperative variables (symptom scores, PVR, uroflowmetry parameters)
comparable in between TURP and TUIP group
Operative variables (operating time, amount of irrigation fluid and blood
transfusion required) were observed and recorded. Postoperative catheterization
period and hospital stay (in days) noted. Post operative variables (symptom scores,
PVR,  uroflowmetry parameters) were compared.
Preoperative, intraoperative and postoperative variables were collected and
analysed. In study group 1(TUIP) 4 patients were lost to follow up and in group
2(TURP) 3 patients were lost to follow up.
RESULT:
In our study, outcome assessed by comparing difference (improvement) in
variables which shows TUIP is equally efficacious to TURP in smll size (less than 35
grams) BPH. Intra operative variable showed significant reduction in operative time
and irrigant usage resulting decreased risk for stricture rate, TUR syndrome and
electrolyte disturbances. In TUIP, immediate postoperative discomfort due to traction
application was not present. Transfusion need was not present with TUIP, whereas
transfusion was needed with TURP .An objection to TUIP is that incidental prostatic
cancer will not be diagnosed due to non availability of tissue for biopsy. This could be
dealt with by a needle biopsy of the prostateHowever, reoperation risk is more with
TUIP. This lead to our concern over long term outcome of TUIP surgery. Hence the
need for long term follow-up. TUIP can be a better choice  in selected group of
patients like those who are not fit for prolonged anaesthsia due to age or comorbid
conditions.
CONCLUSION:
TUIP is an effective method of relieving urinary outflow obstruction caused by
Benign Prostatic Hyperplasia when prostate size is 35g or less.
TUIP is a less invasive, more cost effective treatment that has fewer associated
side effects than TURP.
In selected group of patients, TUIP is an effective alternative to TURP
1INTRODUCTION
Benign prostatic hyperplasia (BPH) is the most common condition
affecting men those are 50 years of age and above. A multicentre study
performed in different countries in Asia showed that the age-specific
percentages of men with moderate-to-severe symptoms were higher than
those in America 2. The prevalence increases from 18% for men in their
40 years to 56% for those in their 70 years of age.
BPH is a hyperplastic process of the glandular epithelial elements
andfibromuscular stromal elements of the prostate. BPH can impact
onquality of life. BPH manifests clinically with lower urinary tract
symptoms (LUTS) and may be associated with sexual dysfunction. 50 to
70% of men with histological features of BPH also have a prostate
volume  of  more  than  25gms  (BPE),  and  up  to  28%  have  moderate  to
severe LUTS 3,  4. The clinical impact is because of bothersome LUTS.
BOO(bladder outlet obstruction) was detected in about52% of the
asymptomatic and60% of the symptomatic men with BPH 6,7,15.Although
it is not lifethreatening,its clinical manifestation as lower urinary tract
symptoms (LUTS) reduces the patient’s quality of life. Troublesome
LUTS can occur in up to 30% of men older than 65 years 5.
Several mechanisms seem to be implicated in the pathophysiology
of BPH. These represent age-relatedhormonal alterations,tissue
modifications, and metabolic syndrome as well as inflammation8.
2Although  androgens  do  not  take  part  in   causation  of  BPH,  the
development of BPH needs the androgens’ presence. Moreover, several
studies support the association betweenhypertension, obesity, non
insulindependent diabetes mellitusand low high-density lipoprotein
cholesterol and the development of BPH. Finally, recent increasing
evidence seems to support the idea that BPH consists of an inflammatory-
based disorder.
In 2010, the American Urological Association launched an
initiative to identify national research priorities in urology, known as the
AUA Foundation National Urology Research Agenda (NURA), this
document defines the top issues facing urology, and BPH is identified as
an area for scientific opportunity1.
Transurethral resection of the prostate is the second most common
surgery9 that a male of age greater than 50 years undergoes, second only
to cataract surgery. TURP has withstood the test of times in being the
gold standard treatment in the management of BPH 2. The advent of use
of LASERs in endourology has put the exclusivity of TURP in the
management of BPH in jeopardy. Holmium laser (HoLEP) is upcoming
as the standard procedure13,14 though it is still questioned by many
urologists. However in developing countries the prohibitive cost of these
lasers make their widespread public use difficult. TURP still remains the
widely used technique for the management of BPH10,11,12.
3TURP, with the advent of newer technologies in diathermy and
visual scopes, has turned from a complication fraught procedure to a
relatively safe one. But still the risks of TURP syndrome and electrolyte
disturbances  do exist especially in cardiac risk patients accentuated by
the use of glycine as anirrigant fluid. The advent of bipolar diathermy has
made the use of normal saline as a safe irrigant fluid107.
The relevance of resection procedures in the treatment of small
gland bladder outlet obstruction has been questioned. Several authors
have propagated the use of transurethral incision of bladder neck and
prostate in the case of small prostate BOO24,25,26.
The fact that TUIP is a less morbid procedure than TURP, shifts
the balance in its favor and has revived this ancient procedure
popularized by Orandi. It has been shown to have an important role in the
management of younger patients, especially if the prostate is smaller than
30g27,28. The efficacy is comparable in such patients with TURP, and the
results are maintained in the long term. The technique is simple with low
morbidity and cost effective. The role of this cost effective surgery in
small gland BOO needs evaluation especially with reference to
developing countries.
As per AUA guidelines,  Option: TUIP is an appropriate and
effective treatment alternative in men with moderate to severe LUTS
and/or who are significantly bothered by these symptoms when prostate
4size is less than 30 grams. The choice of approach should be based on the
patient’s individual presentation including anatomy, the surgeon’s
experience and discussion of the potential benefits and risks for
complications1.
For BPH with small gland size, treatment options are watchful
waiting, medical management and surgical options. In our population,
periodic followup and cost consensus have made non invasive options
less feasible. Hence a low cost, less morbid procedure for small sized
glands with the available facilities would be a better choice.
We opted for transurethral incision of  prostate, which does not
need any special instruments other than those used for TURP. Many
Randomized Control Trial`s have already compared efficacy of these two
procedures in gland size of 30-50 grams27,28,29,30,31.Wehave  planned to
evaluate the efficacy of   TUIPas a treatment modality for small size(35
grams) obstructive   BPH   and   to   compare   its  outcome with that of
TURP in our institution.
The presence of cultural, social, literacy barriers restricted the
collection of details regarding sexual function, retrograde ejaculation .
Hence we evaluated IPSS, QOL, PFR, PVR as variables to assess
outcome.
5AIM
               To    evaluate    the   efficacy   of    TUIP   as    a    treatment
modality   for small   size   obstructive   BPH   and   to   compare   its
outcome with that of TURP
OBJECTIVES
To optimize treatment modality of small size obstructive BPH with
minimally invasive procedure
6REVIEW OF LITERATURE
The prostate, seminal vesicles, ampullary glands, and bulbourethral
glands are considered as sex accessory tissues include and are believed to
play a major but unknown role in the reproductive process.41,42
The prostate development from the urogenital sinus during the
third month of intra uterine growth and development is directed primarily
by DHT41,42,43. Five epithelial buds form in a paired manner on the dorsal
aspect of the urogenital sinus on each side of the verumontanum, and they
then invade the mesenchyme to form the prostate. The top pairs of buds
form the inner zone of the prostate of mesodermal origin; the lower buds
form the outer zone of the prostate  of endodermal origin. This is of
potential importance since the inner zone gives rise to benign prostatic
hyperplasia (BPH) tissue, whereas the outer zone remains the primary
origin of cancer. These two zones of the prostate develop as concentric
circles around the urethra.  The center portion of the prostate contains the
mucosal and submucosal gland and the ejaculatory ducts as well as the
small remnants of the müllerian duct—the utriculusprostaticus, which
forms the small prostatic utricle. By fourth month of fetal life, the
prostate forms acini and collecting ducts by arborization into the urethra;
the growth occurs primarily on the tips, as the ducts extend and branch
during development. This concept of dynamic growth processes occur
along a budding and branching system was developed from studies on the
7mouse and rat prostate43 ( Sugimura et al, 1986 ; Banerjee et al, 1993a,
1993b; Cunha, 1994 ).
The prostate measures4 cm in width,3 cm in length, and 2 cm in
depth; and is traversed by the prostatic urethra. The prostate is with a
narrowed apex facing inferiorly and a broad base  that is contiguous with
bladder base48,51. It is enclosed by a capsule composed of collagen,
elastin, and abundant smooth muscle. an average thicknessof this capsule
is 0.5 mm. There is a plane betweenthe rectum and Denonvilliers' fascia,
filled by loose areolar tissue. The capsule blends with the visceral
continuation of endopelvic fasciaat the anterior and anterolateral surfaces
of the prostate. Puboprostatic ligaments extend anteriorly to fix the
prostate to the pubic bonetoward the apex45, 46.
The apex of the prostate is blended with the striated urethral
sphincter52,53. Histologically, normal prostatic glands is found to extend
into the striated muscle with no intervening “capsule”
orfibromuscularstroma.  At the base of the prostate, outer longitudinal
fibers of the detrusor fuse and blend with the fibromuscular tissue of the
capsule. In surgically resected prostate carcinomas, this complex
arrangement can make interpretation of these margins difficult and has
led some pathologists to propose that the prostate does not possess a true
capsule 44(Epstein, 1989).
8Structure
The prostate is composed of approximately 70% glandular
elements and 30% fibromuscularstroma. The stromaencircles and invests
the glands of the prostate and contracts during ejaculation to express
prostatic secretions into the urethra. It is continuous with capsule and is
composed of abundant smooth muscle andcollagen.
The glands of the prostate are tubuloalveolar with and are lined
with  columnaror simple cuboidal epithelium. Scattered neuroendocrine
cells, of unknown function, are seen in between the secretory cells.
Flattened basal cells line each acinus and are believed to be stem cells for
the secretory epithelium. Each acinus is surrounded by connective tissue
and stromal smooth muscle49.
The glandular elements of the prostate have been divided into
different zones,  by the location of their ducts in the urethra, by their
differing pathologic lesions, and, in some cases, by their embryologic
origin47,48. These different zones is better  demonstrable  with transrectal
ultrasonography. At the angle dividing the preprostatic and prostatic
urethra, the ducts of the transition zone arise and pass beneath the
preprostatic sphincter to travel on its lateral and posterior sides.
Normally,  the  transition  zone  contributes  about  5%  to  10%  of  the
glandular tissue of the prostate. A discrete fibromuscular band of tissue
lies between  the transition zone from the remaining glandular
9compartments and may be visualized at transrectal ultrasonography of the
prostate. Benign prostatic hypertrophycommonly arise fromtransition
zone, which expands to compress the fibromuscular band into a surgical
capsule seen at enucleation of an adenoma. 20% of adenocarcinomas of
the prostate arise from transition zone.
The central zone ducts arise circumferentially around the openings
of the ejaculatory ducts47. This zone comprises 25% of the glandular
tissue of the prostate and expands around the ejaculatory ducts to the base
of the bladder in a cone shaper. The glands are structurally and
immunohistochemically distinct from the remaining prostatic glands
(which branch directly from the urogenital sinus),leads to the concept
that they arise from wolffian duct48 . 1% to 5% of adenocarcinomas arise
from   the  central  zone  and  it  may  also  be  infiltrated  by  cancers  from
adjacent zones.
The peripheral zone,  bulk of the prostatic glandular tissue (70%)
occupies the posterior and lateral aspects of the gland. Ducts of this
zonedrain into the prostatic sinus along the entire length of the
(postsphincteric) prostatic urethra45,46,47. Seventy percent of prostatic
cancers arise in this zone and it is this zone which is most commonly
affected by chronic prostatitis.
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Fig : 1 (McNeal’s zonal classification, 1972. 48
Table: 1   Characteristics of the Human Prostate Zones48,49
Central Zone Transition
Zone
Peripheral
Zone
Volume of
normal prostate
25% 5% 70%
Proposed
embryonic origin
Wolffian duct Urogenital
sinus
Urogenital
sinus
Epithelium Complex, large
polygonal glands
Simple small
rounded glands
Simple small
rounded glands
Stroma Compact Compact Loose
Origin of
prostatic
adenocarcinoma
5% 25% 70%
BPH - 100% -
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Clinically, the prostate is divided into two lateral lobes, separated
by a central sulcus,  palpable on rectal examination, and a middle lobe,
which may project into the bladder in enlarged prostate. These lobes are
not histologically defined structures in the normal prostate but are usually
dueto the  pathologic enlargement of the transition zone laterally and
centrally by the periurethral glands.
Vascular Supply
The main arterial supply to the prostate is from the inferior vesical
artery. In benign prostatic hypertrophy, these arteries provide the
principal blood supply of the adenoma50 (Flocks, 1937). The most
significant bleeding is commonly encountered at the bladder neck,
particularly at the 4- and 8-o’clock positions during resection.
ETIOPATHOGENESIS OF BPH
Lot of theories has been proposed about etiopathogenesis of BPH,
yet nothing is conclusive. Androgens elicit effects in fetal life by acting
through androgen receptors (ARs) in urogenital sinus mesenchyme
(UGM), which induces prostatic epithelial development. In adulthood,
reciprocal homeostatic stromal-epithelial interactions maintain functional
differentiation and growth-quiescence. Androgens are not only required
for normal function of the prostate gland but also have been implicated in
prostate disease as well.54,7
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Though DHT is the primary growth hormone for prostate, it should
be noted that human BPH is not associated with elevated DHT
levels. 55 Prostatic growth even in declining androgen levels suggests that
other factors from the testis can stimulate prostate growth or  sensitize
prostatic cells to the effect of androgen.56 Estrogen may act in
combination with other hormones to stimulate prostate cells and cause
enlargement of the gland. Estrogen-androgen synergisms as well as a role
for other steroidal hormones have also been suggested as mechanisms for
BPH. Estrogen action, mediated via ERa, will cause aberrant cellular
differentiation and proliferation with progression to prostatic hyperplasia,
neoplasia and dysplasia. 57,58,59
Fig : 2 Etiopathogenesis of BPH.7
A  study  conducted  by  Cunha  et  al.43,57 showed that stromal cells
have effect in the differentiation pattern of normal prostatic epithelium.
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Aberrent expression of peptide growth factors or their receptors  may
directly cause  uncontrolled growth, resulting in BPH. The stromal cells
are the source for secreting  growth factors such as fibroblast growth
factors, insulin-like growth factors I and II, as well as tumor growth
factors, which act in an autocrine manner on the stroma itself as well as in
paracrine action on the neighboring glandular cells to induce
proliferation.
The  prostate  glandis   influenced  by  the  EGF  system  .  EGF
stimulates  proliferation of epithelial cells as well as stromal cells  derived
from the prostate. In the prostate, the EGF system  thusplays an important
role for stroma-epithelium interactions.60
A causative role for inflammation in the pathogenesis of BPH was
first suspected in 1937. 61 Three recent reviews  have showed  an evidence
based theories that strongly suggests a role of inflammation  towards  the
propagation of BPH. 62,63,64,65 Kramer and Marberger 66 have recently
criticised the current state of knowledge in regard to the influence of
inflammation on the pathogenesis of BPH. Chronic inflammatory
infiltrates, like activated T cells and macrophages  are associated with
BPH nodules. These infiltrating cells produces cytokines (IL-2 and IFN?)
which inducesfibromuscular growth in BPH. 67  T cells Immigration
induced by proinflammatory cytokines such as IL-6, IL-8 and IL-
15. 65 Surrounding cells become targets and are killed (unknown
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mechanisms), leaving behind vacant spaces that are replaced by
fibromuscular nodules with a specific pattern of a Th0/Th3 type of
immune response.
BPH has an genetic component.This theory was supported bySanda
and colleagues (1994), who  conducted a retrospective case-control
analysis of surgically treated BPH patients and control subjects at Johns
Hopkins. In a community-based cohort study of more than 2000 men,
Roberts and colleagues (1997) found an elevated risk of moderate to
severe urologic symptoms in men with a family history of an enlarged
prostate and a family history of BPH compared with those with no
history.
Pathophysiology of BOO
The partially obstructed urethra, detrusor muscle and the central
nervous system function, interact to produce lower urinary tract
symptoms (LUTS). These were historically referred to as ‘prostatism’.
Benign prostatic hyperplasia (BPH) maycause obstruction through
prominent median lobe acting as a ball valve, a dynamic obstruction
related to the contractile properties of prostatic smooth muscle, a static
obstruction resulting from an enlarged prostate enveloping the prostatic
urethra, or a restricted surgical capsule. All these mechanisms lead to
increase inintravesical pressure and a reduction in flow which leads to the
gradual development of secondary changes in the muscle itself80,81.
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Histologic  Features:
BPH is a true hyperplastic process. Histologic studies document an
increase in the cell number48 . In addition, thymidine uptake studies in the
dog clearly indicate an increase in DNA synthesis in experimentally
induced BPH (Barrack and Berry, 1987). The term benign prostatic
hypertrophy is pathologically incorrect.
McNeal's studies demonstrate that the majority of early periurethral
nodules are purely stromal in character49.   The  minimal  stroma  seen
initially consists primarily of mature smooth muscle, not unlike that of
the uninvolved transition zone tissue. These glandular nodules are
apparently derived from newly formed small duct branches that bud off
from existing ducts, leading to a totally new ductal system within the
nodule. This proliferative process leads to a clumping of glands within a
given area as well as an increase in the height of the lining epithelium.
During the first 20 years of BPH development, the disease
characterized by an increased number of nodules, and the subsequent
growth of each new nodule is generally slow48,49, 54. Then a second phase
of evolution occurs in which there is a significant increase in large
nodules.
There is significant pleomorphism in stromal-epithelial ratios in
resected tissue specimens. Studies from primarily small resected glands
16
demonstrate a predominance of fibromuscularstroma54,67, 68. Larger
glands, predominantly those removed by enucleation, demonstrate
primarily epithelial nodules69. However, an increase in stromal-epithelial
ratios does not necessarily indicate that this is a “stromal disease”;
stromal proliferation may well be due to “epithelial disease.”
Importance of Prostatic Smooth Muscle
Prostatic smooth muscle represents a significant volume of the
gland68. Though, spatial arrangement of smooth muscle cells in the
prostate is not optimal for force generation,both passive and active forces
in prostatic tissue play a major role in the pathophysiology of BPH68 .
The elastic elements in the stromal and epithelial cells and (most
important) the ECM contribute to passive tissue force, independent of
active smooth muscle contraction. However, adrenergic nervous system
stimulation  results in a dynamic increase in prostatic urethral resistance.
Blockade by ?-receptor blockers clearly diminishes this response, but not
the passive tension in the prostate, which may be an equal determinant of
urethral resistance..?-Adrenergic blockade in patients with documented
BPH causes a significant down regulation of normal contractile protein
gene expression, specifically smooth muscle myosin heavy chain70,71.
Effect of obstruction on the bladder:
In early phases of obstruction, hypertrophy of the detrusor
muscleincreases detrusor pressure in order to maintain flow in the
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presence of increased outflow resistance. With persistent obstruction
however decreased compliance in the bladder wall and impaired
emptying occur owing to the deposition of extracellular matrix (ECM) 72.
This effect contributes to the decreased smooth muscle contractility and
resulting in development of abnormal smooth muscle phenotype74. Acute
urinary retention may occur during the process and may be related to
bladder failure, as well as to sudden increase in outflow obstruction.
Fig. 3 : The pathophysiology of BOO(Adapted from Wein:
Campbell-Walsh Urology,10th ed.Physiology and Pharmacology of
the Bladder and Urethra:Roehrborn CG; Chapter 91; p2579)
Natural History of Benign Prostatic Enlargement:
The natural history of a disease refers to the progression of disease
over timeifuntreated. Clinical endpoints of  BPH include bladder
dysfunction manifested by incomplete emptying or detrusor instability,
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more severe bladder outlet obstruction, acute urinary retention (AUR),
recurrent UTI, urosepsis, chronicrenal insufficiency, bladder stones,
incontinence and hematuria.
The natural history of benign prostatic enlargement was obtained
from the longitudinal follow-up of the Olmstead County Study of Urinary
Symptoms and Health Status75.A relatively small subset of men between
the ages of 40 and 79 were randomly selected from the Olmstead County
community and underwent transrectal ultrasonography at baseline 9 and 6
years later. A mixed-effects regression model showed that prostate
volume increased by about 1.6% per year on average.
Men with larger prostatesize at start of the study  experiencedmore
increase in prostatic volume. Jacobsen and colleagues76 reported on
LUTS progression in the Olmstead County Study over an interval of 42
months. The AUA symptom score was categorized as mild (0-7) versus
moderate to severe (8-35). At 42 months, 22% of men with mild
symptoms crossed over to moderate to severe symptoms. A regression
model showed that the average symptom score change over time was 0.18
symptom units per year. The AUA symptom score increased during this
interval of time in all age categories. The greatest mean symptom score
progression was observed in the 60- to 69-year old age group.
The Medical Therapy of Prostatic Symptoms (MTOPS) study
represents the longest placebo-controlled trial to date of men with
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BPH.77Prostate volume was not an inclusion criterion in this study. The
placebo arm provides insights into the natural history of men with
moderate to severe LUTS and decreased peak urinary flow rates. The
objective of the MTOPS study was to examine the impact of medical
therapies  on  BPH  progression.  In  this  study,  BPH  progression  was
defined as a 4-point increase in AUA symptom score or the development
of AUR, chronic renal insufficiency or socially unacceptable
incontinence, or recurrent UTI or urosepsis. The final analysis conducted
with a mean follow up of 4.5 years, which shows  only clinically relevant
progression rates were observed for symptom progression and AUR. The
overall progression rate (events/100 patient-years) was 4.5 in the placebo
group. The MTOPS study demonstrated that the development of AUR is
quite common in men with clinical BPH. This is consistent with the
Olmstead County Study of Urinary Symptoms and Health Status, which
reported a cumulative incidence rate for AUR of6.8 Per thousand person-
years. With a multivariate analysis, age at baseline, symptom severity and
peak flow rate independently predicted risk of AUR.
Lower Urinary Tract Symptoms
Lower urinary tract symptoms has become the preferred term for
urinary symptoms, instead of  “symptoms of benign prostatic
hyperplasia” and “prostatism” which were previously used to describe
lower urinary tract symptoms 80.
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According to the International Continence Society (ICS), lower
urinary tract symptoms denote three things: a symptom, perceived by the
patient; a sign, observed by the physician; and a condition, defined by
urodynamic observations 81.
In the present definition, ICS divides lower urinary tract symptoms
into three groups: storage symptoms experienced when urine is stored in
the bladder, voiding symptoms experienced during the voiding phase and
post micturition symptoms experienced immediately after micturition82.
Fig. 4  : From Roehrborn CG. Pathology of benign prostatic
hyperplasia.Int J Res 2008;20[Suppl. 3]:S11–8.)77.
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Assessment of Lower Urinary Tract Symptoms
             Attempt to measure the impact of lower urinary tract symptoms
on life leads to formulation of many scoring systems.
The Boyarsky Score 83 is the questionnaire, first published to assess
lower urinary tract symptoms. The questionnaire is designed to be
completed by the physician and has never been validated. It evaluatesthe
severity of nocturia, frequency, hesitancy, intermittency,
terminaldribbling, urgency, reduction of the size and force of the stream,
dysuria and incomplete voiding.
The Madsen-Iversen Score 84 is another unvalidated questionnaire,
also designed for completion by the physician. The questionnaire assesses
urinary stream, straining to void, hesitancy, intermittency, bladder
emptying, stress incontinence or post void dribbling, urgency, frequency
and nocturia. The importance of the patient’s perception of the symptoms
has been recognized and new instruments for assessing severity,
frequency and quality of life of lowerurinary tract symptoms have been
designed. Health measurements or scales can be used to directly inquire
about the impact of the symptoms or the distress they cause.
The International Prostate Symptom Score (IPSS) questionnaire 85
is a validated instrument that measures the occurrence of seven symptoms
from the lower urinary tract (incomplete emptying, frequency, urgency,
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nocturia, straining, weak stream, hesitancy). The IPSS Questionnaire
includes one separate question concerning the quality of life, graded on a
scale from 0 to 6.
The American Urological Association (AUA) symptom index is a
validated questionnaire and includes seven questions covering frequency,
nocturia, weak urinary stream, hesitancy, intermittency, incomplete
emptying and urgency and two questions on quality of life 82.
The ICS male SF questionnaire includes 11 questions on lower
urinary tract symptoms (hesitancy, straining, decreased stream,
intermittency, incomplete emptying, urgency, urge incontinence, stress
incontinence, unpredictable incontinence, nocturia, post-void
dribbling)and one question on quality of life 86.
The Danish Prostatic Symptom Score (DAN-PSS) 87 measures the
12 symptoms of lower urinary tract. Moreover, it evaluates the symptoms
both quantitatively and qualitatively, using both a symptom score and a
distress score. This scoring system has a sensitivity of 92% and
aspecificity of 94% 88,89. The DAN-PSS questionnaire also measures the
occurrence of dysuria, post micturition dribbling and urinary
incontinence, as well as measuring activities of daily living, none of
which are covered by the IPSS questionnaire90.The DAN-PSS
questionnaire is well understood by men 40 years or older 91 and is
reliable  and  valid  for  the  same  purposes  as  the  IPSS  questionnaire
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(Hansen et al. 1998). At the ICS conference in Tampere2000, Koskimaki
and co-workers presented data showing that the correlation coefficient
between total DANPSS score and total IPSS score was 0.70 92.
Lower Urinary Tract Function of Ageing
Age-related changes in the central nervous system and the organs
adjacent to the bladder increase the risk for lower urinary tract
symptoms93. Alterations in nervous system e.g. Parkinson’s disease, often
associated with aging, places the elderly individuals at risk for developing
lower urinary tract symptoms 94,95.
The drugs used for neurologic or functional disease may cause
lower urinary tract symptoms in individuals with an otherwise healthy
lower urinary tract93.
Prevalence of Lower Urinary Tract Symptoms
The overall prevalence of symptoms of the lower urinary tract
differs in published reports 97,98,99,100,101. One explanation for the variation
could be that different symptoms are included. Many of these studies took
into account of urinary incontinence alone, but somestudies have
considered other lower urinary tract symptoms also. Other explanation for
the apparent difference in prevalence is the selection of the population.
Sometrials  have selected their samples from patients listed in general
practice, visiting other than urology clinics or selected from health care
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district98, 99. Selection of a study population that includes everyone living
within a certain geographical area gives a more accurate estimateof
prevalence than studies where the population is selected from among
patients attending a physician’s office.
Uroflowmetry
Uroflowmetry is a simple, screening procedure used to measure the
flow  rate  of  urine  in  relation  to  time.  This  test  is  simple  and
noninvasive.It is a common, noninvasive urodynamic test used in the
diagnostic evaluation of patients presenting with symptoms of BOO96.
Uroflowmetry is performed by having a person urinate into a closet
that  is  connected  to  asensor   instrument  with  a  measuring  jar.  This
mechanism  calculates the amount of urine, flow rate in seconds and
length of time until completion of the void. This informationis converted
into a graph and interpreted by a physician. The values vary depend on
the person’s gender and age. The information helps to evaluate function
of the lower urinary tract or determine if there is an obstruction of normal
urine outflow96.Siroky and coworkers (1979) concluded that
Uroflowmetry was able to distinguish physiologically unobstructed and
obstructed patients.
During normal urination, the initial stream starts slowly but almost
immediately speeds up until the bladder is nearly empty. The urine flow
then slows again and the bladder is emptied. In persons with a urinary
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tract obstruction, this pattern of flow is alteredmore gradually. This
informationis made into graph and the results are analysed.The urinary
flow rate is recorded as an electronic wave throughout the course of
micturition.  The  specificity  of  this  test  is  low,  For  example,  an
abnormally low flow rate may be caused by an obstruction (e.g.,
hyperplastic prostate,urethral stricture, meatal stenosis) or by detrusor
hypocontractility.
The AHCPR Guideline Panel conclusions regarding uroflowmetry96.
? Flow rate measurements are validonly if the voided volume is
morethan 150mL.
? Uroflowmetry is the single best noninvasive urodynamic test to
detect lower urinary tract obstruction, but cut off values are not
defined accurately.
? Age or volume correction is not currently recommended for
clinical practice.
? The peak flow rate (PFR; Qmax) more specifically identifies
patients with BPH than does the average flow rate (Qavg).Scott
and coworkers (1967) and Shoukry and associates (1975) found
that Qmax correlated better than symptoms with the presence or
absence of obstruction as determined by pressure-flow studies.
? A Qmax of less than 15 mL/s denotes presence of either
obstruction or  bladder decompensation. Gleason and colleagues
(1982) found that Qmax distinguished between normal men and
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patients with BPH, urethral stricture, or prostatitis. They also noted
that a subgroup of patients with a decompensated detrusor muscle
could not be separated from the obstructed men on the basis of
Qmax alone.
Abrams and associates (1997) studied the value of uroflowmetry
before prostatectomy. Failure rates for surgery were found to decrease
with the addition of flow rate measurement to symptom assessment in
preoperative evaluation96.
In a study, where the flow rates were studied before and 6 months
after prostatectomy ( Jensen et al, 1988a ), subjective evaluation revealed
an overall symptomatic improvement rate of 80% after surgery. The
difference in success rates for men falling above or below the cutoff value
of Qmax = 10 mL/s was not significant (P = .2). When a Qmax cutoff of
15 mL/s was used, success rates for men above or below the cutoff value
differed significantly.
Fig : 5 Uroflow patterns.
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McLoughlin and coworkers (1990) , using urodynamic testing and
a  cutoff  value  of  12  mL/s,  evaluated  108  men with  clinical  BPH before
and 1 year after surgery and considering Qmax less than 12 mL/s as cut
off  for obstruction, only 3% of patients would have been subjected to an
unnecessary TURP. They are also not recommending  the routine use of
pressure-flow studies or cystometrograms but that the screening of flow
rates. These tests  may be considered patients with a Qmax of greater than
12 mL/s.
Till now, a cut off level for obstruction (e.g., based on the BOOI)
has not been defined. No evidence-based studies suggest when surgical
relief is indicated to prevent bladder decompensation.
Gland size
Size of Prostate gland can be measured transrectally or
suprapubically. Although suprapubic measurement of prostate volume is
less than ideal, it correlates well with transrectal measurement. Lepor et
al showed gland volumes not correlated with  AUA symptom score and
only weakly related to peak flow rate102.Although there is no direct
evidence of large prostates causing BOO in noncatheterized patients,
those presenting with acute retention had successful trial without catheter
provided the prostate size was smaller103. Thus, there is indirect evidence
that larger prostates tend to be obstructive.
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Postvoid Residual Urine
Postvoid residual (PVR) urine is the volume of urine remaining in
the bladder immediately after the completion of micturition. Studies
indicate that PVR urine normally ranges from 0.09 to 2.24 ml, with the
mean being 0.53 ml. Seventy-eight percent of normal men have PVRs of
less than 5 ml and 100% have volumes of less than 12 ml.
Facts about PVR :
? Residual urine volume measurement has significant intra/inter
individual variability hence, its clinical usefulness is limited.
? Residual urine volume does not correlate well with other signs or
symptoms of clinical BPH.
? Large residual urine volumes associated with  higher failure rate
for watchful waiting. But cut off volume predicting a poorer
outcome is not defined.
? It does not detect impending bladder or renal damage.
The Fourth International Consultation initially recommended PVR
determination in the initial assessment and during monitoring of patients
under watchful waiting or other conservative treatment regimens96.
PVR measurement can be done using noninvasive (ultrasound) and
by invasive (catheterization) methods. The most common method usedis
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ultrasound. Invasive techniques are accurate if performed correctly but
with complication like urethral injury, UTI, and transient bacteremia .The
mean difference between estimated PVR and “true” PVR (i.e., by
catheterization) was 6.9 mL in 39 measurements taken in 20 children with
neurogenic bladders (Massagli et al, 1990). In 164 measurements in adult
patients, the correlationcoefficient was 0.79 (Ireton et al, 1990).
TURP, as we know today, was developed in the United States in
the 1920s and 1930s. Nesbit (1975) pointed out  several significant
factors important in its development: (1) invention of the incandescent
lamp by Edison in 1879; (2) cystoscope, developed independently by
Nitze and Lieter in 1887; and (3)  development of the fenestrated tube by
Hugh Hampton-Young, which allowed the obstructing tissue to be
sheared off blindly.
TURP is the gold standard for the surgical management of BPH.
TECHNIQUE OF TRANSURETHRAL RESECTION OF
PROSTATE  several  techniques of transurethral resection have been
described. The goal of TURP is to remove the obstructing tissue while
minimizing damage to surrounding structures
Nesbit resection technique
The Nesbit technique107 is probably the best  and most commonly
performed  TURP  method.  It  was  first  described  by  Reed  M.  Nesbit  of
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Michigan in 1943 .The procedure is divided into 3 stages: (1) proximal
orintravesical, (2) extravesical and (3) apical.
Resection begins by removing the intravesical portion of the
prostate and bladder neck tissue .
Then, gland resected from ventrally 11 – 1’o clock region towards
6’o clock both side. The prostatic capsule is the lateral limit of resection.
Surgical removal  starts at the proximal end. In the apical stage, the apical
tissue around the verumontanum isremoved atlast.
Milner resection technique108
The resection started at the 9-o’clock position and proceededup to
capsular fibers. The groove extends from the bladder neck to a point
parallel to the verumontanum. The groove is extended upwards toward
the 11-o’clock position and then downward toward the 7-o’clock
position. Resection started from the lateral lobe tissue from the inside out
quickly  and  to  reach  the  surgical  capsule  ,  where  the  perforating  and
bleeding vessels can be cauterized if necessary. When both lateral lobes
are resected, the posterior and median lobes are removed  similar to
Nesbit technique.
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Complications of TURP
Table 2: Complications of TURP
Complication in
percentage
Mebust
1989
Doll 1992 Haupt
1997
Kuntz
2004
Capsular
perforation
0.9 10 - 4
Transfusion 6.4 22 2.2 2.0
TUR syndrome 2.0 - 0.3 0
Clot retention 3.3 11.0 1.9 5.0
Urosepsis 0.2 3.0 0.2 0
Failure to void 6.5 3.0 - 5.0
incontinence - 38 0.3 1.0
These results reveals complications following TURP in different
time periods. Doll etal study results reflects their aggressive surgical
technique. Recent study by Kuntz etal revealed increase in compliance of
the patient for follow up.
Bleeding
Arterial bleeding can be more  in cases of preoperative infection or
urinary retention because of a congested gland. Anti-androgen
pretreatment with finasteride or flutamide may reduce bleeding. Venous
bleeding  due tovenous sinusoid openings and capsular perforation. The
amount of intraoperative bleeding depends on gland size and resection
weight.  In  Mauermeyer approach the vessels at 5 and 7 o’clock are
controlled early; Nesbit technique aims to first reach the capsule at the 11
and 1 o’clock positions
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Post-void residual volume
Both surgical procedures allow a reduction of the post-void
residual volume of more than; 60% after TURP and 55% after TUIP 107.
Incontinence
Early incontinence may occur in up to 30–40% of patients, late
iatrogenic stress incontinence occurs in fewer  than 0.5% of patients107.
Urethral stricture
The rate of urethral stricture varies from 2.2% to 9.8%. There is
relationship to operative time periods and size of instrument.
The  etiology of stricture formation depends on the site of stricture
* Meatal strictures usually occur due to an inappropriate relationship
between the size of the instrument and the diameter of the urethral
meatus.
* Bulbar strictures occur because insufficient isolation by the
lubricant causes the monopolar current to leak.
Bladder neck stenosis
The incidence varies from 0.3% to 9.2%, usually after smaller
glands (<30 g) are treated110.
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Retrograde ejaculation
Retrograde ejaculation occurs in 53–75%  patients. Retrograde
ejaculation might be avoided if the tissue around the verumontanum is
spared during resection107,111.
Erectile dysfunction
 High Frequency-generated current close to the capsule may
damage the neurovascular bundles. The rate of impotence varies from 3.4
to 32% in the Literature109
Intra and peri-operative mortality following prostatectomy  is less
than < 0.25%.
The risk of a TUR-syndrome is in the range of 2%. Risk factors for
TUR-syndrome are excessive bleeding with opening of venous sinuses,
prolonged operation time, large glands and past or present smoking. The
estimated need for blood transfusion following TURP is in the range of 2-
5%.
TUIP has been available since the 19th century. Edwards and
colleagues (1985) credit Bottini with describing the technique in 1887,
but Hedlund and Ek (1985) credit Guthrie in 1834. Guthrie's technique
was to disrupt the bladder neck, whereas Bottini used diathermy to divide
it. However, in 1973, Orandi104 published the first significant series on
TUIP. The procedure seemed to be most useful in those who had a small
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prostate and who had obstructive bladder outflow symptoms. Classically,
the patient was a younger man when compared with those having a
TURP. Turner – Warwick popularized the procedure in Europe105.
Fig.6  :Guithre’s knife
Fig.7 : Bottini’slithotrite for heating the prostate
Technique
The surgical technique is relatively simple. Using a Collings knife,
an incision is made at the 5 and 7 o'clock positions or on one side of the
midline only. It starts just distal to the ureteral orifice and ends just
proximal to the verumontanum. The incision depth should be to the point
at which fine fibers of the external capsule are seen. Care must be taken
not to incise too deeply because extravasation of irrigation fluid or rectal
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injury may occur. With completion of the incisions and with the scope in
the more distal urethra, there should be no visible obstruction to the
bladder outflow.
Fig 8  : Method of TUIP
Lourenco et al111 reviewed data from 795 randomised participants
across  10  Randomized  Control  Trials  of  moderate  to  poor  quality  8  of
which stated an upper limit for prostate size. No difference in the degree
of symptomatic improvement was seen between the two procedures.
Improvement in peak urine flow rate was lower for TUIP compared to
TURP whilst the rate of blood transfusion and TUR syndrome was higher
after TURP. Urinary retention, urinary tract infection, strictures and
incontinence did not differ between the two approaches, although
clinically important differences could not be ruled-out. TUIP was
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associated with a shorter duration of operation and length of hospital stay
but a higher re-operation rate.
They concluded that TUIP and TURP appear to offer equivalent
symptomatic improvement for men with mild to moderate BPE. Choosing
TUIP involves a trade-off between the lower risk of peri-operative
morbidity and the higher risk of subsequent re-operation.
Retreatment rate :
The retreatment rate of TURP is lower than therates of other
alternatives such as TUIP  (3–14.5% after five years)110
Table 3 : Reoperation after treatment with TURP and TUIP111
TUIP TURP
Study
Number
of
patients
reoperation percentage
Number
of
patients
reoperation percentage
Aliaga .R34 21 1 4.8 20 1 5
Dolfinger25 31 1 3.2 29 6 20.7
Nielsen28 25 - - 24 3 12.5
Riehmann29 56 9 16 60 13 21.6
Saporta30 20 0 0 20 3 15
Jahnson27 42 3 7.1 43 10 23.2
These results revealed increased reoperation rate in TUIP than
TURP. In Riehmann series follow up period was 18 months but Nielsen
series it was only 3 months. Most common reason following TURP was
bladder neck stenosis. In TUIP it was adhesion between gland edges.
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Barry et al 106 in his landmark study compared both the procedures
and gave the comparative data as follow.
Table 4 :Treatment Outcomes Balance Sheet110
Factors analysed TUIP TURP
Chance of symptom improvement 78-83% (80) 75-96% (88)
Degree of symptom improvement 73% 85%
Morbidity (20% significant) 2.2-33% (14) 5.2-30.7% (16)
Mortality (30-90 days) 0.2-1.5% 0.53-3.31%
Incontinence—total 0.061–1.1% 0.68-1.4%
Operative treatment for surgical
complications
1.34-2.65% 0.68-10%
Stamey’s  in 1993 proposed that ‘TURP is now a therapy of
history’ may turn out true atleast in case of small gland disease.
Ten  Randomized  Control  Trial`s  comparing  TUIP  to  TURP  are
available26-32,34,39. They showed similar improvements of LUTS in
patients  with  small  prostates  (<  20-50  grams).  TUIP  has  several
advantages over TURP, such as a lower incidence of complications,
minimal risk of bleeding and blood transfusion, decreased risk of
retrograde ejaculation and shorter operating time and hospital stay. TURP
comprises 95% of all surgical procedures and is the treatment of choice
for prostates sized 30-80 gms. Intra- and postoperative complications are
correlated with the size of the prostate and the length of the procedure.
Long term trials revealed reoperative rate is more with TUIP.
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MATERIALS AND METHODS
1. Study group   :
Patients who were admitted with bothersome lower urinary tract
symptoms (LUTS) due to benign prostatic hyperplasia at 1. Kilpauk
Medical College Hospital and 2. Government RoyapettahHospital
between 2010 - 2011were included in the study group.
2.Study design :      Prospective Randomised  Clinical study
3.Materials :
Inclusion criteria :
          Patients with Bothersome LUTS due to BPH
IPSS score more than 7
Prostate size less than 35gms
Exclusion criteria :
Patients  with
? Hematuria
? Previous history of bladder/transurethral surgery
? Vesical calculi
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? Uncontrolled diabetes mellitus
? Elevated renal parameters
? Neurogenic Bladder
? Cases of BPH,who do not come under inclusion criteria.
Patient Evaluation:
All patients with LUTS symptoms were graded according to
International Prostate Symptom (IPSS) scoring system,quality of life
score were also recorded. Complete history and physical examination was
done.
Prostate size was determined by digital rectal examination (DRE)
and Ultrasonography( Philips HD 6.1) using Prostate ellipsoid formula
(Prostate size in gm= ?/6 ×anteroposterior × transverse × sagittal
diameter).
Urinalysis, Complete Hemogram, Blood Urea and Serum
Creatinine were measured.Uroflowmetry( LaborieDelphis KT )was
donepre and postoperatively in all cases who did not have Urinary
retention.PSA level was measured only in patients with suspicion of
carcinoma by DRE or USG findings.
Urodynamic evaluation was done only in cases suspected for
neurogenic cause.
40
All patients underwent Preoperative anaesthetic evaluation for
fitness to undergo regional as well as general anaesthesia.
The procedure was done under spinal anesthesia, with the patient in
lithotomy position.
First, cystoscopy was done using Storz 20Fr sheath with 30 degree
telescope to assessthe urethra, bladder as well as prostate. By using, 24 Fr
sheath with Baumrucker working element with loop or Colling’s knife
(Storz) both procedures were done. The procedureswere done by
surgeons who are experienced in transurethral surgeries.
Patients were randomly selected (alternate patient)into two groups
(TUIP vs TURP)
In TURP group, resection was done up to anatomic capsule of the
prostate using conventional technique. In TUIP group, two deep
incisions, at 5- and 7-0'clock positions were made using Colling’s knife.
Incisions were made from the trigone just below the ureteral orifices,
cutting  the  bladder  neck  and  prostate  to  the  sides  of  proximal  end  of
verumontanum. Incision deepened up to the point at which fine fibers of
the external capsule are seen. Sterile water was used as irrigation fluid. At
the end of procedures, a 22-Fr three way Foley catheter was passed,
balloon inflated to 30 - 40ml of distilled water and connected to a closed
drainage system. Traction was applied to TURP group and not applied to
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TUIP. Postoperatively, continuous bladder irrigation with normal saline
was continued till return became fairly clear.
 In every patient, total operating time, amount of irrigation fluid
used in liters and the amount of blood transfusion required were observed
and recorded. Postoperative catheterization period noted.
Every patient was followed up for three months postoperatively.
Follow up studies included patients’ subjective evaluation of outcome of
operation and detailed symptoms score (IPSS). Uroflowmetry and
Ultrasonography were done for each patient to find out maximum  flow
rate and post void residual volume of urine respectively.
Collected data were subjected to statistical analysis.
Statistical Package for the Social Sciences, version 12.0.2 (SPSS
Inc, Chicago, IL, USA) was used for the statistical analysis
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RESULTS
We  planned  to  evaluate     the    efficacy    of    TUIP    as    a
treatment   modality   for small   size(35 grams)   obstructive   BPH   and
to   compare   its outcome with that of TURP in our institution.
          In  our  study,  total  of  60  patients  were  included  who  fulfilled  the
inclusion criteria. They were randomly selected into two groups which
consisted of 30 patients each.
Preoperative, intraoperative and postoperative variables were
collected and analysed.In study group 1(TUIP) 4 patients were lost
tofollow up and in group2(TURP) 3 patients were lost to follow up.
Statistical Package for the Social Sciences, version 12.0.2 (SPSS
Inc,  Chicago,  IL,  USA)  was  used  for  the  statistical  analysis.  Level  of
significance is considered with the P value < 0.05.
Age group : Both  the  TUIP  and  TURP  arms  of  the  study  were
matched for appropriate age. The mean age for group 1 (TUIP) was 67.54
years and group 2 (TURP) was 65.07 years.
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Fig 9 : Age distribution.
Age distribution:
Most of the patients in both groups belong to 61 to 70 years age
group
Table – 5 : Age Distribution
GROUP
1 2 Total
Count 6 8 14
% within AGE-YEAR-
GROUP
42.9% 57.1% 100.0%
% within GROUP 23.1% 29.6% 26.4%
UPTO
60
% of Total 11.3% 15.1% 26.4%
AGE-
YEAR-
GROUP
61-70 Count 13 14 27
% within AGE-YEAR
– GROUP
48.1% 51.9% 100.0%
% within Group 50.0% 51.9% 50.9%
% of Total 24.5% 26.4% 50.9%
1 – Upto 60 years
2 –  61 – 70 years
3 -  > 70 years
GROUP 1 – TUIP
GROUP 2 - TURP
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Levene's Test for
Equality of
Variances
t-test for Equality of
Means
F Sig. t df Sig. (2-tailed)
Equal
variances
assumed
.107 .745 1.376 51 .175
AGE -YEAR
Equal
variances not
assumed
1.374 50.431 .176
There was no statistical significance between the various age
groups between TUIP and TURP arm as shown by a p value of 0.175.
Size of the gland:
Mean volume of the prostate gland as measured by ultrasonogram
was found to be 28.58 grams in group 1 and 29.44 gramsin group 2 with
no statistical significance.(p = 0.315)
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IPSS
Symptom score improved from mean preoperative value of 25.73
to postoperative value 8.08 in group 1 (TUIP) showing a statistical
significance with a p value of 0.004
Symptom score improved from mean preoperative value of 25.41
to postoperative value 6.67 in group 2 (TURP) showing a statistical
significance with a p value of 0.028.
Fig. 11:PRE  &  POSTOPERATIVE   IPSS  SCORE
Table – 6 : Group Statistics
GROUP N Mean
Std.
Deviation
Std.
Error
Mean
PRE-OP-
IPSS
1 26 25.73 2.808 .551
2 27 25.41 3.555 .684
POST-OP-
IPSS
1 26 8.08 3.969 .778
2 27 6.67 1.144 .220
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Comparison between the mean of improvement in IPSS
The mean of difference between pre-op and post-op IPSS
(improvement) in group 1- 17.65 and group 2 – 18.74 showing no
statistical significance with p value of 0.239
Table 7 : Group Statistics
GROUP N Mean Std. Deviation
Std. Error
Mean
1 26 17.65 3.393 .666IPSS-
DIFFERENCE
2 27 18.74 3.241 .624
Independent Samples Test
Levene's Test for
Equality of
Variances
t-test for Equality of Means
F Sig. t Df
Sig. (2-
tailed)
IPSS-
DIFFERENCE
Equal
variances
assumed
.433 .514 -1.193 51 .239
Equal
variances
not
assumed
-1.192 50.641 .239
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Quality Of Life:
QOL improved from mean preoperative value of 4.23 to
postoperative value 1.42 in group 1 (TUIP) showing a statistical
significance with a p value of 0.00
Symptom score improved from mean preoperative value of 4.15 to
postoperative value 1.07 in group 2 (TURP) showing a statistical
significance with a p value of 0.00.
Table – 8 : Group  - 1 Pre & Post comparison Paired Samples Test
t df
Sig. (2-
tailed)
Pair 1 PRE-OP-IPSS - POST-OP-
IPSS
26.527 26 .000
Pair 2 PRE-OP-QOL - POST-OP-
QOL
22.593 26 .000
Pair 3 PRE OP-PEAK FLOW
RATE-ml - POST OP-PEAK
FLOW RATE-ml
-16.855 26 .000
Pair 4 PRE OP-POST VOID
RESIDUE-ml  -  POST   OP-
POST VOID RESIDUE-ml
8.754 26 .000
Table – 9 : Group  - 2 Pre & Post comparison Paired Samples Test
t df
Sig. (2-
tailed)
Pair 1 PRE-OP-IPSS - POST-OP-IPSS 30.042 27 .000
Pair 2 PRE-OP-QOL - POST-OP-QOL 29.067 27 .000
Pair 3 PRE OP-PEAK FLOW RATE-
ml - POST OP-PEAK FLOW
RATE-ml
-24.502 27 .000
Pair 4 PRE OP-POST VOID
RESIDUE-ml - POST  OP-
POST VOID RESIDUE-ml
7.646 27 .000
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Fig 12 : PRE  &  POST  OP QOL  SCORE
Comparison between the mean of improvement in QOL:
The mean of difference between pre-op and post-op QOL
(improvement) in group 1 was 2.81 and group 2 was 3.07 showing no
statistical significance with p value of 0.452
Table 10 : Group Statistics
GROUP N Mean
Std.
Deviation
Std. Error
Mean
1 26 2.81 .634 .124QOL-
DIFFERENCE
2 27 3.07 .550 .106
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Independent Samples Test
Levene's Test for
Equality of
Variances
t-test for Equality of
Means
F Sig. t df
Sig. (2-
tailed)
Equal variances assumed 2.352 .131 .758 51 .452
PRE-OP-
QOL Equal variances not
assumed .756 48.893 .453
POST-
OP-QOL Equal variances assumed 16.885 .000 1.844 51 .071
Peak Flow Rate:
PFR improved from mean preoperative value of 6.238 to
postoperative value 16.396 in group 1 (TUIP) showing a statistical
significance with a p value of 0.00 (Ref.Table - 8)
PFR improved from mean preoperative value of 6.367 to
postoperative value 19.176 in group 2 (TURP) showing a statistical
significance with a p value of 0.00 (Ref. Table – 9).
FIG. 13:PRE&  POST  OPERATIVE  PEAK  FLOW  RATE
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The mean of difference between pre-op and post-op PFR
(improvement) in group 1- 10.16 and group 2 – 12.81 showing no
statistical significance with p value of 0.749
Table 11 :Independent Samples Test
Levene's Test
for Equality
of Variances
t-test for
Equality of
Means
F Sig. t df
Equal variances
assumed
.103 .749 -3.329 51
PEAK FLOW RATE-
ml-DIFFERENCE
Equal variances
not assumed
-3.322 49.712
Post Void Residual urine:
PVR improved from mean preoperative value of 128.54 to
postoperative value 31.12 in group 1 (TUIP) showing a statistical
significance with a p value of 0.00 (Ref.Table 8).
PFR improved from mean preoperative value of 114.44  to
postoperative value 24.63 in group 2 (TURP) showing a statistical
significance with a p value of 0.00 (Ref. Table 9).
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FIG 14 :  PRE &  POST  OPERATIVE  POST  VOID RESIDUAL
URINE
Pre operative PVR values of group1 and group2 were not
statistically significant with  p value  of 0.734
Table 12 : Independent Samples Test
Levene's Test for
Equality of
Variances
t-test for Equality
of Means
F Sig. t Df
Equal
variances
assumed
.567 .455 .734 51
PRE OP-POST VOID
RESIDUE-ml Equal
variances not
assumed
.732 49.289
POST  OP-POST VOID
RESIDUE-ml
Equal
variances
assumed
1.614 .210 1.118 51
Equal
variances not
assumed
1.102 31.280
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Operative time:
Operative time for procedure in group 1- 16 minutes and group 2-
45minutes were showing statistically significant difference
Irrigation fluid:
Irrigation fluid used for procedure in group 1- 3.67 litres and group
2- 12.22 litres were showing statistically significant difference
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DISCUSSION
BPH  is  a  common  disease  of  old  age  which  may  lead  to
troublesome LUTS 1. The enlarged gland has been proposed to contribute
to the overall lower urinary tract symptoms (LUTS) complex via at least
two routes: (a) direct bladder outlet obstruction (BOO) from enlarged
tissue (static component) and (b) from increased smooth muscle tone and
resistance within the enlarged gland (dynamic component). Voiding
symptoms have often been attributed to the physical presence of BOO.
In  management  of  BPH,  due  to  problems  of  compliance  and  cost
effectiveness, surgical options are preferred in our setup. For many years
TURP  has  been  the  standard  treatment  for  the  patients  with  symptoms
which  are  too  bothersome.  TURP  is  effective  but  carries  a  risk  of
significant complications.
          Hence we conducted a study to compare a less morbid procedure,
TUIP, with the gold standard TURP, by means of intraoperative variables
(amount of irrigant fluid used, operative time) and postoperative variables
(improvement in symptoms, quality of life, peak uroflowmetry, residual
urine volume).
60 patients were included in our study who fulfilled our selection
criteria. They were randomly selected into two groups (Group 1- TUIP,
Group 2 – TURP). The two groups were analysed for statistical equality.
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Mean of age – 67.54 years and 65.07 years, gland size – 28.58 and 29.44
grams, IPSS – 25.73 and 25.41, QOL – 4.23 and 4.15 Peak uroflowmetry
– 6.23ml and 6.36ml, post void residual urine – 128 and 114 ml in TUIP
and TURP respectively which were statistically not significant.
In our study mean and mode of age of patients were between 61 –
70 years which is the common age group for BPH 1-3. The variables which
were considered above can affect operative procedure and outcome 3,7.
In studies conducted for correlation between size of gland and
BOO symptomatology did not show significant relation.3,16,41,76 There is
no appropriate definition for small size gland (20 g by Orandi, 30 grams
by Yang et al, up to 50 grams in Nielsen et al, Aliaga et al). So we
planned to select 35 grams as upper limit of gland size.
TUIP – is an accepted option in management of BPH as an
alternate to TURP especially in small size glands1. Several RCTs have
shown TUIP as an equally efficacious, less morbid and cost effective
procedure as compared with TURP. It is aneasier technique to master
than TURP3
We compared intraoperative variables (amount of irrigation fluid
used and operative time), which had shown statistically significant
advantage for TUIP (3.6 vs 12.2 litres) and (16 vs 45 minutes). This
outcome correlated with all the reference trials. These two factors are
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directly related with risk of TUR syndrome development which revealed
less risk with TUIP group.
Immediate postoperative variables blood transfusion, catheter
dwell time, retention rate were analysed. In TURP group, 2 patients
required transfusion (patient number 8 and 20 in chart).
One patient developed excess intraoperative blood loss due to
highly vascularised gland and other had preoperative borderline
haemoglobin.
Traction was applied in TURP group, not in TUIP group. Post
operative discomfort like suprapubic and rectal discomfort, urgency and
urge incontinence related to traction were not found in TUIP group.
Jahnsonetal recommended delayed decatheterisation in TUIP due
to risk of adhesion between lateral lobes. In our study, all patients in both
groups were decatheterised on fourth postoperative day and watched for
retention.
In  TUIP  arm,  4  patients  were  not  able  to  void,  all  of  them
recatheterised.  3 of them voided successfully in trial without Catheter
after  two weeks (2 in first  and other in second attempt).  But one patient
(no.52 in chart) failed in trial without Catheter  and underwent TURP.
During the reprocedure, cystoscopy revealed synechiae formation.
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In TURP group, 3 patients did not void on catheter removal. All of
them were able to void on trial without Catheter. The reason may be due
to edema at prostatic fossa and bladder neck or detrusor hypotonia.
These results were reasonably matched with studies by Allagaetal
(1/20), Nielsen et al (3/24), Saporta et al (3/26).27,28,31,111
We discharged all the patients on the next day of catheter removal
except those (8) recatheterised or transfused. In both groups none of the
patient developed toxic complication or TUR syndrome.
A few patients in both groups had symptoms of urgency (6 in
group 1 and 14 in group 2) which was managed by anticholinergic
therapy.
Though, we had not encountered Bladder neck stenosis, theoretical
risk is more with TURP particularly in small size gland110,111.
Postoperative followup was done on the 15th day and then 1 and 3
months after. At third month, postoperative variable (improvement in
IPSS, QOL, PFR and PVR.) were evaluated.
All biopsy specimen from TURP group revealed benign etiology.
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Attrition:
4 patients in group 1 and 3 patients in group 2 failed to attend
followup clinics, hence datas from 26 in group1 and 27 in group 2 were
analysed for outcome comparision.
IPSS:
At 3-months postoperative follow-up visits there were very
significant improvement of symptoms in both the groups with no
significant difference between the groups. Mean improvement in group 1-
17.6 and in group 2 - 18.7 which were comparable with no statistical
significance. These indicate that both the procedures are equally effective
in reducing symptom score. These confirm the experience of  Jahnsonet
al (1998)27, Riehmann et al (1995)29, Lourenco et al(2010)108 found no
significant difference in symptom score improvement between the
groups.
Quality Of Life:
Mean improvement in group 1- 2.81 and group 2 – 3.07 showing
no statistical significance with p value of 0.452 were comparable with
review of randomised trials by Lourenco et al111.
Peak Flow Rate:
Concerning uroflowmetry, preoperative mean Qmax were
in6.238ml/sec  and 6.367 ml/sec, Postoperative Qmax were 16.396
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ml/sec and19.176 ml/sec  in TUIP and TURP group respectively at
follow-up postoperative visit. These improvements of flow rates are
highly significant following TURP as well as TUIP(P<0.001) and there is
insignificant difference between the groups (P>0.1). These results agree
with those of Christensen et al (1990)24, Riehmann et al (1995)29,
postoperatively in TURP and TUIP group respectively. Dorflingeret al
(1987)12 found the change from 10.1 ml/secand 9.2 ml/sec
preoperatively to 15 ml/sec and 19ml/sec postoperatively in TURP and
TUIP group respectively. In Larsen et al (1987) series these change were
7.4 ml/sec and 8.6 ml/sec to 18.5ml/sec and 20.6 ml/sec. Hellstrom et al -
14.4 vs 16.3 ml/sec, Soonawalla et al – 19.1 and 20.5 ml/sec).. However
one study showed significant difference between the groups27 (Jahnsen et
al). They postulated that the removal of the gland resulted in creation of a
good channel in TURP group. The mean of difference between preop and
postop PFR (improvement) in group 1 was 10.16 and group 2 was 12.81
ml/sec. Though difference of 2ml/sec in improvement between two
groups showed no statistical significance and correlated with reference
studies 26,31
Post Void Residual urine:
Mean preoperative PVR was128.54   ml (75-370) in TUIP and
114.44 ml (70-380) in TURP group. These were 31.12 ml (0-45)and
24.63 ml (0-45)  postoperatively in the TUIP and TURP group
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respectively and there were no significant difference between the groups
both preoperatively and postoperatively. But there are highly significant
differences pre- to postoperative intragroup values. The mean of
difference between pre-op and post-op PVR (improvement) in group 1-
97 and group 2 – 90 ml. These results are similar to the reference studies
(Soonawallaetal)31.  These  changes  of  PVR  agree  with  Jahnsonet  al
(1998)27, Riehmann et al (1995)29, Lourenco et al108(2010) and others.
In our study, outcome assessed by comparing difference
(improvement) in variables which shows TUIP is equally efficacious to
TURP in smll size (less than 35 grams) BPH. Intra operative variable
shows significant reduction in operative time and irrigant usage resulting
decreased risk for stricture rate, TUR syndrome and electrolyte
disturbances. In TUIP, immediate postoperative discomfort due to
traction application is not present. Transfusion need is not present with
TUIP, whereas transfusion is needed with TURP .An objection to TUIP is
that incidental prostatic cancer will not be diagnosed due to non
availability  of  tissue  for  biopsy.  This  could  be  dealt  with  by  a  needle
biopsy of the prostate. However, Reoperation risk is more with TUIP.
This leads to our concern over long term outcome of TUIP surgery hence
the need for long term follow-up. TUIP can be a better choice in selected
group of patients like those not fit for prolonged anaesthsis due to age or
comorbid conditions.
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CONCLUSION
TUIP is an effective method of relieving urinary outflow
obstruction caused by Benign Prostatic Hyperplasia when prostate size is
35g or less.
TUIP is a less invasive, more cost effective treatment thath as
fewer associated side effects than TURP.
In selected group of patients, TUIP is an effective alternative to
TURP.
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Sl.No GROUP NAME
AGE -
YEAR IP NO
INSTITUT
ION gland size-g
PRE-OP-
IPSS
POST-OP-
IPSS
PRE-OP-
QOL
POST-OP-
QOL
PRE OP-PEAK
FLOW RATE-ml
POST OP-
PEAK FLOW
RATE-ml
PRE OP-POST
VOID RESIDUE-
ml
POST  OP-POST VOID
RESIDUE-ml
IRRIGATI
ON FLUID-
L
OPERATI
VE TIME D.O.S
1 1 Mr.Velu 63 1600 kmc 29 23 8 4 1 7.8 15.6 90 24 2.5 12 2/3/2011
2 1 Mr.Renganathan 70 2075 kmc 32 27 9 4 2 9 17.1 85 18 3.5 18 2/8/2011
3 1 Mr.Muthusamy 69 967552 grh 27 24 6 4 1 6.5 18.3 104 30 3.5 15 2/9/2011
4 1 Mr.Thiruvenkatam 74 2243 kmc 30 30 25 5 4 0 0 370 160 4.5 18 2/15/2011
5 1 Mr.Abdhul Samad 68 969440 grh 23 26 7 4 2 8.2 19 100 32 3 16 2/25/2011
6 1 Mr.Noorulah 65 969225 grh 27 21 5 4 1 9.6 17.8 75 15 2.5 18 3/9/2011
7 1 Mr.Arumugam 70 7893 kmc 29 23 7 4 2 7.6 17.3 90 22 3.5 19 4/21/2011
8 1 Mr.Elumalai 60 8587 kmc 24 28 7 4 1 8.4 19.1 110 34 3 14 4/30/2011
9 1 Mr.Arunachalam 72 9718 kmc 34 27 9 5 3 5.1 14.8 130 35 5 20 5/17/2011
10 1 mr.ramukutty 80 976003 grh 32 31 9 4 2 0 12.5 320 40 4 16 6/3/2011
9 1 Mr.Arunachalam 70 9718 kmc 34 27 7 4 1 4.3 16.3 120 28 3 16 5/17/2011
10 1 Mr.Ramukutty 80 976003 grh 32 31 9 5 2 0 12.5 320 45 4 20 6/3/2011
11 1 Mr.Ganeshan 65 976254 grh 29 24 6 4 1 7.6 18.2 80 20 4.5 20 6/10/2011
12 1 Mr.Chinnappan 65 13956 kmc 24 23 6 4 1 6.8 17.9 94 30 3.5 16 7/11/2011
13 1 Mr.durai 60 14712 kmc 27 26 7 4 1 8.8 20.4 105 25 4 18 7/16/2011
14 1 Mr.Thankaraj 79 973447 grh 31 29 7 4 1 0 15.6 284 32 4 19 7/22/2011
15 1 Mr.Sambasivam 64 15947 kmc 28 26 6 4 1 7.9 19 100 18 4 14 7/26/2011
16 1 Mr.Chelladurai 55 999759 grh 24 22 5 4 0 8.4 22.5 80 15 3 12 7/29/2011
17 1 Mr.Perumal 60 17818 kmc 26 27 8 4 1 6.3 16.8 105 27 4 16 8/11/2011
18 1 Mr.Mohamed sherif 81 981286 grh 32 29 9 5 2 5.4 13.2 120 40 3.5 18 8/26/2011
19 1 Mr.Govindarajulu 71 17916 kmc 29 24 7 4 1 7.2 17.6 135 25 3 12 8/20/2011
20 1 Mr.Shanmugavel 75 981105 grh 32 28 6 4 1 8.4 16.8 100 18 3.5 16 9/7/2011
21 1 Mr.Vivekanandhan 60 19513 kmc 27 23 5 4 0 7.6 21.4 95 0 4 15 9/8/2011
22 1 Mr.Ramanathan 69 982190 grh 31 27 11 5 3 0 14.3 120 30 4.5 19 9/16/2011
23 1 Mr.Kallappan 59 982611 grh 26 29 14 5 2 4.8 11.8 130 50 5 18 9/21/2011
24 1 Mr.Pandurangan 65 983753 grh 32 24 7 4 1 7.9 16.8 90 20 4 17 10/7/2011
25 1 Mr.Elumalai 67 22875 kmc 24 21 7 4 1 8.6 16.2 110 16 3 16 10/18/2011
26 1 Mr.Dhanapal 72 986023 grh 34 27 9 5 3 5.1 14.8 130 35 5 20 11/9/2011
PRE-OP
POST-
OP PRE-OP
POST-
OP PRE-OP POST-OP PRE-OP POST-OP
1 2 Mr.Chandran 70 2249 kmc 29 23 6 4 1 9.4 21 80 15 11 40 2/15/2011
2 2 Mr.Alaudhin 57 3757 kmc 27 24 7 4 1 7.8 19.6 110 18 12 45 3/3/2011
3 2 Mr.Dharmar 64 968783 grh 34 26 7 4 1 9.1 18.4 90 22 12 50 3/4/2011
4 2 Mr.Manivel 71 970384 grh 29 25 8 4 2 7.8 17.2 95 25 14 50 2/9/2011
5 2 Mr.Immanuvel 73 971701 grh 32 29 8 5 1 0 15.7 130 40 12 45 4/1/2011
6 2 Mr.Thaksinamoorty 57 971650 grh 30 21 5 4 1 8.8 19.8 80 12 11 35 4/6/2011
7 2 Mr.Sampath 68 12765 kmc 31 23 6 4 1 6.2 18.4 120 30 12 40 6/14/2011
8 2 Mr.Appasamy 75 13596 kmc 28 28 7 4 2 5.8 18.2 90 45 12 50 7/5/2011
9 2 Mr.Thirumal 65 978538 grh 24 27 7 4 1 7.4 20.7 100 25 12 45 7/6/2011
10 2 Mr.Kannappan 60 13375 kmc 27 31 6 5 1 0 21.3 270 18 14 40 7/12/2011
11 2 Mr.Mari 58 979209 grh 32 22 6 4 1 6.4 18.9 110 28 12 45 7/22/2011
12 2 Mr.Kothandan 64 978957 grh 29 20 5 4 0 7.2 22.4 70 0 11 40 7/22/2011
13 2 Mr.Venkatasamy 60 978973 grh 32 28 9 4 2 7.6 17.2 110 40 16 60 7/27/2011
14 2 Mr.Elumalai 56 15797 kmc 24 18 7 4 1 8.3 19.6 95 20 12 40 7/28/2011
15 2 Mr.Kaliyaperumal 63 978221 grh 27 24 7 4 1 6.3 17.8 100 25 12 45 8/3/2011
16 2 Mr.Rajagopal 62 979739 grh 32 27 5 4 1 7.6 21.3 110 20 11 45 8/26/2011
17 2 Mr.Kasi 60 18262 kmc 29 31 6 5 1 0 17.9 380 45 14 50 8/27/2011
18 2 Mr.Subbiah 68 982493 grh 33 24 5 4 1 8.6 21.6 80 18 11 45 9/9/2011
19 2 Mr.Rayappan 71 19352 kmc 26 22 7 4 1 6.6 20.4 80 22 12 40 9/10/2011
20 2 Mr.Krishnan 65 19355 kmc 34 27 6 4 1 5.2 19.6 90 27 12 45 9/13/2011
21 2 Mr.Nagappan 67 982622 grh 28 21 5 4 1 7.9 23.7 75 20 13 50 9/21/2011
22 2 Mr.Govindasamy 63 20571 kmc 29 25 7 4 1 5.8 17.6 120 25 12 45 9/29/2011
23 2 Mr.Nateshan 54 983473 grh 32 28 7 4 1 8.1 18.7 95 20 12 40 10/7/2011
24 2 Mr.Thulasi 70 984433 grh 34 30 9 5 1 4.8 14.6 130 40 13 50 10/12/2011
25 2 Mr.Elumalai 70 989406 grh 26 23 7 4 1 7.3 18 90 18 12 50 10/19/2011
26 2 Mr.Kaliyamoorthi 66 22884 kmc 30 29 8 4 1 5.4 19.5 100 27 11 45 10/27/2011
27 2 Mr.Thanavel 80 21265 kmc 27 30 7 4 1 6.5 18.6 90 20 12 50 11/1/2011
IRRIGATION
FLUID-L
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TIME D.O.S
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PRE OP-PEAK
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23 2 Mr.Nateshan 54 1 983473 grh 32 28 7 21 4 1 3 8.1
16 1 Mr.Chelladurai 55 1 999759 grh 24 22 5 17 4 0 4 8.4
14 2 Mr.Elumalai 56 1 15797 kmc 24 18 7 11 4 1 3 8.3
2 2 Mr.Alaudhin 57 1 3757 kmc 27 24 7 17 4 1 3 7.8
6 2 Mr.Thaksinamoorty 57 1 971650 grh 30 21 5 16 4 1 3 8.8
11 2 Mr.Mari 58 1 979209 grh 32 22 6 16 4 1 3 6.4
23 1 Mr.Kallappan 59 1 982611 grh 26 29 14 15 5 2 3 4.8
13 2 Mr.Venkatasamy 60 1 978973 grh 32 28 9 19 4 2 2 7.6
8 1 Mr.Elumalai 60 1 8587 kmc 24 28 7 21 4 1 3 8.4
13 1 Mr.Durai 60 1 14712 kmc 27 26 7 19 4 1 3 8.8
17 1 Mr.Perumal 60 1 17818 kmc 26 27 8 19 4 1 3 6.3
21 1 Mr.Vivekanandhan 60 1 19513 kmc 27 23 5 18 4 0 4 7.6
16 2 Mr.Rajagopal 62 2 979739 grh 32 27 5 22 4 1 3 7.6
15 2 Mr.Kaliyaperumal 63 2 978221 grh 27 24 7 17 4 1 3 6.3
22 2 Mr.Govindasamy 63 2 20571 kmc 29 25 7 18 4 1 3 5.8
1 1 Mr.Velu 63 2 1600 kmc 29 23 8 15 4 1 3 7.8
3 2 Mr.Dharmar 64 2 968783 grh 34 26 7 19 4 1 3 9.1
12 2 Mr.Kothandan 64 2 978957 grh 29 20 5 15 4 0 4 7.2
15 1 Mr.Sambasivam 64 2 15947 kmc 28 26 6 20 4 1 3 7.9
9 2 Mr.Thirumal 65 2 978538 grh 24 27 7 20 4 1 3 7.4
20 2 Mr.Krishnan 65 2 19355 kmc 34 27 6 21 4 1 3 5.2
6 1 Mr.Noorulah 65 2 969225 grh 27 21 5 16 4 1 3 9.6
11 1 Mr.Ganeshan 65 2 976254 grh 29 24 6 18 4 1 3 7.6
12 1 Mr.Chinnappan 65 2 13956 kmc 24 23 6 17 4 1 3 6.8
24 1 Mr.Pandurangan 65 2 983753 grh 32 24 7 17 4 1 3 7.9
26 2 Mr.Kaliyamoorthi 66 2 22884 kmc 30 29 8 21 4 1 3 5.4
21 2 Mr.Nagappan 67 2 982622 grh 28 21 5 16 4 1 3 7.9
25 1 Mr.Elumalai 67 2 22875 kmc 24 21 7 14 4 1 3 8.6
7 2 Mr.Sampath 68 2 12765 kmc 31 23 6 17 4 1 3 6.2
18 2 Mr.Subbiah 68 2 982493 grh 33 24 5 19 4 1 3 8.6
5 1 Mr.Abdhul Samad 68 2 969440 grh 23 26 7 19 4 2 2 8.2
3 1 Mr.Muthusamy 69 2 967552 grh 27 24 6 18 4 1 3 6.5
1 2 Mr.Chandran 70 2 2249 kmc 29 23 6 17 4 1 3 9.4
24 2 Mr.Thulasi 70 2 984433 grh 34 30 9 21 5 1 4 4.8
25 2 Mr.Elumalai 70 2 989406 grh 26 23 7 16 4 1 3 7.3
2 1 Mr.Renganathan 70 2 2075 kmc 32 27 9 18 4 2 2 9
7 1 Mr.Arumugam 70 2 7893 kmc 29 23 7 16 4 2 2 7.6
9 1 Mr.Arunachalam 70 2 9718 kmc 34 27 7 20 4 1 3 4.3
4 2 Mr.Manivel 71 3 970384 grh 29 25 8 17 4 2 2 7.8
19 2 Mr.Rayappan 71 3 19352 kmc 26 22 7 15 4 1 3 6.6
19 1 Mr.Govindarajulu 71 3 17916 kmc 29 24 7 17 4 1 3 7.2
26 1 Mr.Dhanapal 72 3 986023 grh 34 27 9 18 5 3 2 5.1
8 2 Mr.Appasamy 75 3 13596 kmc 28 28 7 21 4 2 2 5.8
20 1 Mr.Shanmugavel 75 3 981105 grh 32 28 6 22 4 1 3 8.4
27 2 Mr.Thanavel 80 3 21265 kmc 27 30 7 23 4 1 3 6.5
18 1 Mr.Mohamed sherif 81 3 981286 grh 32 29 9 20 5 2 3 5.4
10 2 Mr.Kannappan 60 1 13375 kmc 27 31 6 25 5 1 4 0
17 2 Mr.Kasi 60 1 18262 kmc 29 31 6 25 5 1 4 0
22 1 Mr.Ramanathan 69 2 982190 grh 31 27 11 16 5 3 2 0
5 2 Mr.Immanuvel 73 3 971701 grh 32 29 8 21 5 1 4 0
4 1 Mr.Thiruvenkatam 74 3 2243 kmc 30 30 25 5 5 4 1 0
14 1 Mr.Thankaraj 79 3 973447 grh 31 29 7 22 4 1 3 0
10 1 Mr.Ramukutty 80 3 976003 grh 32 31 9 22 5 2 3 0
POST OP-PEAK FLOW
RATE-ml
PEAK FLOW RATE-ml-
DIFFERENCE
PRE OP-POST VOID
RESIDUE-ml
POST  OP-POST
VOID RESIDUE-ml
POST VOID RESIDUE-
DIFFERENCE
IRRIGATIO
N FLUID-L
OPERATIVE
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pre-op
retention
post-op
retention
HOSPITAL
STAY
18.7 10.6 95 20 75 12 40 7/10/2011 0 0 5
22.5 14.1 80 15 65 3 12 23/07/11 0 0 6
19.6 11.3 95 20 75 12 40 28/07/11 0 0 6
19.6 11.8 110 18 92 12 45 3/3/2011 0 0 5
19.8 11 80 12 68 11 35 6/4/2011 0 0 5
18.9 12.5 110 28 82 12 45 22/07/11 0 0 6
11.8 7 130 50 80 5 18 21/09/11 0 0 8
17.2 9.6 110 40 70 16 60 27/7/11 0 0 10
19.1 10.7 110 34 76 3 14 30/04/11 0 0 5
20.4 11.6 105 25 80 4 18 16/07/11 0 0 5
16.8 10.5 105 27 78 4 16 11/8/2011 0 0 5
21.4 13.8 95 0 95 4 15 8/9/2011 0 0 5
21.3 13.7 110 20 90 11 45 26/8/11 0 0 5
17.8 11.5 100 25 75 12 45 3/8/2011 0 0 5
17.6 11.8 120 25 95 12 45 29/9/11 0 0 5
15.6 7.8 90 24 66 2.5 12 3/2/2011 0 0 5
18.4 9.3 90 22 68 12 50 4/3/2011 0 0 5
22.4 15.2 70 0 70 11 40 22/7/11 0 0 5
19 11.1 100 18 82 4 14 26/7/11 0 0 5
20.7 13.3 100 25 75 12 45 6/7/2011 0 0 5
19.6 14.4 90 27 63 12 45 13/9/11 0 0 5
17.8 8.2 75 15 60 2.5 18 9/3/2011 0 0 5
18.2 10.6 80 20 60 4.5 20 10/6/2011 0 0 5
17.9 11.1 94 30 64 3.5 16 11/7/2011 0 0 5
16.8 8.9 90 20 70 4 17 7/10/2011 0 0 5
19.5 14.1 100 27 73 11 45 27/10/11 0 0 6
23.7 15.8 75 20 55 13 50 21/9/11 0 0 8
16.2 7.6 110 16 94 3 16 18/10/11 0 0 6
18.4 12.2 120 30 90 12 40 14/6/11 0 0 6
21.6 13 80 18 62 11 45 9/9/2011 0 0 6
19 10.8 100 32 68 3 16 25/2/11 0 0 6
18.3 11.8 104 30 74 3.5 15 9/2/2011 0 0 6
21 11.6 80 15 65 11 40 15/2/11 0 0 6
14.6 9.8 130 40 90 13 50 12/10/2011 0 0 6
18 10.7 90 18 72 12 50 19/10/11 0 0 5
17.1 8.1 85 18 67 3.5 18 8/2/2011 0 0 9
17.3 9.7 90 22 68 3.5 19 21/4/11 0 0 5
16.3 12 120 28 92 3 16 17/5/11 0 0 5
17.2 9.4 95 25 70 14 50 5/2/2011 0 0 5
20.4 13.8 80 22 58 12 40 10/9/2011 0 0 5
17.6 10.4 135 25 110 3 12 20/8/11 0 0 5
14.8 9.7 130 35 95 5 20 9/11/2011 0 0 5
18.2 12.4 90 45 45 12 50 5/7/2011 0 0 5
16.8 8.4 100 18 82 3.5 16 7/9/2011 0 0 6
18.6 12.1 90 20 70 12 50 1/11/2011 0 0 6
13.2 7.8 120 40 80 3.5 18 26/8/11 0 0 5
21.3 21.3 270 18 252 14 40 7/12/2011 1 0 5
17.9 17.9 380 45 335 14 50 27/8/11 1 0 5
14.3 14.3 120 30 90 4.5 19 16/9/11 1 0 5
15.7 15.7 130 40 90 12 45 4/1/2011 1 0 5
0 0 370 160 210 4.5 18 15/2/11 1 1 8
15.6 15.6 284 32 252 4 19 22/7/11 1 0 5
12.5 12.5 320 45 275 4 20 3/6/2011 1 0 5
PROFORMA
NAME: AGE:                          SEX:
ADDRESS:                                                       IP.NO:
D.O.A:                                       D.O.S:                          D.O.D:
PRESNTING COMPLAINTS:
IPSS SCORE:
GENERAL EXAMINATION:                                          P.R:
B.P:
PER ABDOMEN:
CATHETER:
        PER RECTAL:
INVESTIGATIONS:
HB%:              BLOOD:  UREA-                   SUGAR-
SERUM CREATININE-              SERUM PSA-
ELECTROLYTES-
URINE C/S:
USG KUB:
PROSTATE SIZE:
UROFLOW:
CYSTOSCOPY:
OPERATIVE PROCEDURE:  TUIP  / TURP
Operative time:                                           Irrigation:
POST OP.PERIOD:
CATHETER REMOVAL:
USG:
FOLLOW UP:
IPSS SCORE:
UROFLOW:
BIOPSY:
IMPRESSION:
ULTRA SONOGRAM  PHILIPS HD 6.1
UROFLOWMETER – LABORIE – DELPHIS KT
